Biosimilars Conference 2010

Tuesday 16 and Wednesday 17 March 2010, Brussels, Belgium

In an environment where resources are scarce and patents are fast expiring, effective product planning is paramount to ensuring the success of your organisation. Biologic drugs - noted as some of the most-expensive medicines - are major targets for cost savings. The developments facilitating follow-on biologics are gaining momentum, with significant commercial opportunities emerging.

Significant barriers to entry exist in the biosimilars market. Initial investment and the need for specific expertise favour big players. Understanding of the marketplace is critical for success, acceptance by key stakeholders is crucial for market uptake of biosimilars. Achieving preferential reimbursement status through constant review of the pricing strategy is essential.

Following on the success of our 3rd Biosimilars conference VIBpharma is proud to announce the 4th annual Biosimilars conference taking place on Tuesday 16 and Wednesday 17 March 2010 in Brussels, Belgium.

Through a series of presentations and interactive discussions covering key issues such as current market trends, biobetters, the global regulatory environment, pricing and reimbursement strategies and biosimilars in emerging markets, participants will gain new insight and share hands-on experiences with leading companies in the pharma and biotech industry.

This cant-miss conference is an ideal and significant opportunity to bring together the major players in the industry to:

• Identify current and future trends to maximise the profitability of the biosimilars industry
• Achieve a critical analysis of the current market trends and developments to understand the impact of biosimilars on the healthcare industry
• Outline the biosimilars status in emerging markets and how Europe can learn and benefit
• Explore successful pricing and reimbursement strategies  in a biosimilar environment
• Evaluate the global biosimilars market to assess its potential and profitability
• Assess the global legislative environment for biosimilars to understand the current market developments
• Learn about the potential of mAbs in the current situation of expiring patents